Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Repare Therapeutics ( (RPTX) ) has provided an announcement.
On January 28, 2026, Repare Therapeutics completed its acquisition by non-profit biotechnology group XenoTherapeutics, Inc. and Xeno Acquisition Corp. via a statutory plan of arrangement, following shareholder approval on January 16, 2026 and a final court order from the Superior Court of Québec on January 23, 2026. Under the terms of the deal, Repare shareholders received approximately US$2.20 in cash per common share, based on the company’s net cash at closing after liabilities and transaction costs, along with one non-transferable contingent value right for each share that entitles holders to a pro rata share of potential future cash payments. Consideration has been delivered to Broadridge Corporate Issuer Solutions as depositary and will be distributed to former shareholders as soon as practicable, while Repare’s shares are expected to cease trading on the Nasdaq Global Select Market around January 28, 2026, with subsequent deregistration in the United States and an application to cease being a reporting issuer in Québec, effectively taking the company private and ending its public reporting obligations in both jurisdictions.
The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses and continued cash burn), partially offset by a strong balance sheet with very low debt. Technically, the stock shows positive momentum (price above key moving averages and positive MACD). Corporate events add support via the approved acquisition and asset sale improving near-term cash visibility, while valuation remains weak given the negative P/E and no dividend.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics is a clinical-stage precision oncology company that uses a proprietary synthetic lethality platform to discover and develop targeted cancer therapies focused on genomic instability and DNA damage repair. Its pipeline includes Phase 1 candidates RP-3467, a Polθ ATPase inhibitor, and RP-1664, a PLK4 inhibitor, positioning the company within the niche of highly specialized, mechanism-driven oncology drug development.
Average Trading Volume: 1,126,116
Technical Sentiment Signal: Hold
Current Market Cap: $113.4M
See more insights into RPTX stock on TipRanks’ Stock Analysis page.